Savolitinib, an oral TKI against c-MET, was combined with osimertinib in patients with EGFR-mutant NSCLC with MET amplifications/mutations after progression on osimertinib in the phase 2 trial ORCHARD [111]. Here, EGFR is linked to non-small cell lung carcinoma.